Scientists develop AI method to predict overall survival rate of prostate cancer patients
Peer-Reviewed Publication
Updates every hour. Last Updated: 9-Jul-2025 19:10 ET (9-Jul-2025 23:10 GMT/UTC)
AI tools can provide close to precise survival estimates of patients with prostate cancer, according to scientists
Scientists have identified why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumours and developed a new combination therapy. Identifying this mechanism is important as it identifies patients who will not respond to single agent ICB treatment such as anti-PD1 antibody therapy, but are most likely to benefit from the new combination therapy that they have identified, anti-CD30. By simply adding anti-CD30 for these patients, they believe they can improve response to cancer and avoid costly delays.
When cancer spreads from a primary tumor to new sites throughout the body, it undergoes changes that increase its genetic complexity.
A new study from researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) provides fresh insights about how cancers evolve when they metastasize — insights that could aid in developing strategies to improve the effectiveness of treatment.